These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 14697223)

  • 21. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluorescein-labeled beta-lactamase mutant for high-throughput screening of bacterial beta-lactamases against beta-lactam antibiotics.
    Chan PH; Chan KC; Liu HB; Chung WH; Leung YC; Wong KY
    Anal Chem; 2005 Aug; 77(16):5268-76. PubMed ID: 16097768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative in-vitro activities of GD-40 and other beta-lactamase inhibitors against TEM-1 and SHV-2 beta-lactamases.
    Danelon G; Mascaretti O; Radice M; Power P; Calcagno ML; Mata EG; Gutkind G
    J Antimicrob Chemother; 1998 Feb; 41(2):313-5. PubMed ID: 9533481
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical inhibitor-resistant mutants of the beta-lactamase TEM-1 at amino-acid position 69. Kinetic analysis and molecular modelling.
    Chaibi EB; Péduzzi J; Farzaneh S; Barthélémy M; Sirot D; Labia R
    Biochim Biophys Acta; 1998 Jan; 1382(1):38-46. PubMed ID: 9507060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The effectiveness of so-called potentiated penicillins (augmentin and tazobactam) in vitro].
    Blahová J; Hupková M; Krcméry V
    Cas Lek Cesk; 1995 Sep; 134(17):558-61. PubMed ID: 7553760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
    Bethel CR; Hujer AM; Helfand MS; Bonomo RA
    FEMS Microbiol Lett; 2004 May; 234(1):99-103. PubMed ID: 15109726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Raman crystallographic studies of the intermediates formed by Ser130Gly SHV, a beta-lactamase that confers resistance to clinical inhibitors.
    Helfand MS; Taracila MA; Totir MA; Bonomo RA; Buynak JD; van den Akker F; Carey PR
    Biochemistry; 2007 Jul; 46(29):8689-99. PubMed ID: 17595114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.
    Akova M; Yang Y; Livermore DM
    J Antimicrob Chemother; 1990 Feb; 25(2):199-208. PubMed ID: 2158496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
    Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S
    J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
    Fonseca F; Sarmento AC; Henriques I; Samyn B; van Beeumen J; Domingues P; Domingues MR; Saavedra MJ; Correia A
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4512-4. PubMed ID: 17875998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of piperacillin/tazobactam against 615 Pseudomonas aeruginosa strains isolated in intensive care units.
    Bonfiglio G; Laksai Y; Franceschini N; Perilli M; Segatore B; Bianchi C; Stefani S; Amicosante G; Nicoletti G
    Chemotherapy; 1998; 44(5):305-12. PubMed ID: 9732144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of Bacillus anthracis metallo-β-lactamase by compounds with hydroxamic acid functionality.
    Kim SK; Demuth M; Schlesinger SR; Kim SJ; Urbanczyk J; Shaw RW; Shin H
    J Enzyme Inhib Med Chem; 2016; 31(sup4):132-137. PubMed ID: 27557855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanic acid and sulbactam combined with ampicillin and piperacillin against beta-lactamase producing anaerobic bacteria.
    Nord CE
    J Chemother; 1989 Jul; 1(4 Suppl):273-5. PubMed ID: 16312398
    [No Abstract]   [Full Text] [Related]  

  • 34. The Bla2 beta-lactamase from the live-vaccine strain of Francisella tularensis encodes a functional protein that is only active against penicillin-class beta-lactam antibiotics.
    Bina XR; Wang C; Miller MA; Bina JE
    Arch Microbiol; 2006 Sep; 186(3):219-28. PubMed ID: 16841206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Post antibiotic, post beta-lactamase inhibitor and post antibiotic sub-MIC effect of ceftriaxone/tazobactam on beta-lactamase-producing Escherichia coli in vitro].
    Zhang SC; Zhang LL; Chen SW; Wu HY; Liu XK
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Nov; 40(6):1071-4. PubMed ID: 20067122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Behaviour of beta-lactamase-positive and -negative Staphylococcus aureus isolates in susceptibility tests with piperacillin/tazobactam and other beta-lactam/beta-lactamase inhibitor combinations.
    Bonfiglio G; Livermore DM
    J Antimicrob Chemother; 1993 Sep; 32(3):431-44. PubMed ID: 8262865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of products of inhibition of GES-2 beta-lactamase by tazobactam by x-ray crystallography and spectrometry.
    Frase H; Smith CA; Toth M; Champion MM; Mobashery S; Vakulenko SB
    J Biol Chem; 2011 Apr; 286(16):14396-409. PubMed ID: 21345789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of pO2 and pH on synergy of tazobactam and beta-lactam antibiotics against beta-lactamase producing Enterobacteriaceae.
    König C; Blaser J
    J Antimicrob Chemother; 1995 Sep; 36(3):513-9. PubMed ID: 8830015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-vitro susceptibilities of species of the Bacteroides fragilis group to newer beta-lactam agents.
    Betriu C; Sánchez A; Gómez M; Palau ML; Picazo JJ
    J Antimicrob Chemother; 1999 Jan; 43(1):133-6. PubMed ID: 10381111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. X-ray structure of the Asn276Asp variant of the Escherichia coli TEM-1 beta-lactamase: direct observation of electrostatic modulation in resistance to inactivation by clavulanic acid.
    Swarén P; Golemi D; Cabantous S; Bulychev A; Maveyraud L; Mobashery S; Samama JP
    Biochemistry; 1999 Jul; 38(30):9570-6. PubMed ID: 10423234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.